SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the approaching FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the companys amended application and longer-term upper-limb data alongside recent FDA discussion of flexibility in rare-disease reviews. Many are bullish and read commercial hiring as a sign of launch preparation, while skeptics stress that approval is uncertain given the earlier negative review and debate over the evidence; some also cite Inovios separate FDA approval as a positive sentiment signal.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is climbing toward a 52-week high as traders position for anticipated Q3 results, with BRIUMVIs sales growth adding to optimism. Buyout and short-squeeze theories are circulating, but the acquisition talk is unconfirmed, and some traders question whether earnings expectations are already reflected in the run-up.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about new competition for Precigens PAPZIMEOS. Traders debate the threat: some see a serious challenge, while others argue Precigen retains an advantage from its commercial head start and full approval, and view the selloff as an overreaction.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Traders are discussing Oktas reported addition to the S&P 500 in place of KVUE, with some anticipating index-related buying and others warning of a sell-the-news reaction. Separately, claims of a DHS data exposure involving Oktas login system are adding bearish concern, though those claims are not established in the discussion.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

MLYS is under pressure amid concerns that the slow early commercial ramp for AstraZenecas competing hypertension drug could signal a challenging launch and weaker near-term sales prospects for lorundrostat. Traders disagree on whether that undermines Mineralyss commercial outlook, with some emphasizing the upcoming FDA decision and clinical data while others question its ability to compete independently.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported major Binance security breach, with withdrawals temporarily suspended and billions in crypto reportedly affected, is driving attention to BNB and broader crypto-market concerns. Traders are debating whether the incident threatens trust in Binance and warrants further selling, while others view the selloff as an overreaction; claims of an inside job remain speculation.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is being discussed amid volatile crude prices and shifting Middle East supply risks, especially tensions and shipping disruptions around the Strait of Hormuz. Traders debate why PR often fails to track oils moves, while some point to the companys production growth, guidance and dividends as support for a longer-term bullish view.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is the dominant topic, with traders citing share dilution and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to its strategic U.S. HALEU supply role and government contracts as long-term support, while others question the valuation and whether the decline has further to run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Newsmax Stock Rallies 11% After-Hours – Here’s What We Know

Equity

Newsmax reported total quarterly revenues of $52.2 million for the three-month period ended December 31, 2025, representing a 9.6% year-over-year increase.


ETF Opportunities Trust - American Conservative Values ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Its total broadcasting revenues grew 12.6% year-over year to $42.5 million for the fourth quarter of 2025.</li><li>Newsmax said it expects full-year revenue of $212 million to $216 million, representing 13% year-over-year growth at the midpoint of the range.&nbsp;</li></ul>Newsmax (NMAX) shares jumped 11% during extended hours of trading on Thursday after it posted strong fourth quarter revenue that buoyed investors.&nbsp;Newsmax reported total quarterly revenues of $52.2 million for the three-month period ended December 31, 2025, representing a 9.6% year-over-year increase. It beat analysts’ estimates of $44 million as per Stocktwits data.&nbsp;Its total broadcasting revenues grew 12.6% year-over year to $42.5 million for the fourth quarter of 2025, underscoring continued growth even in a non-election year. This was driven by affiliate fee revenue growth, higher ratings and pricing for broadcasting ad revenue, and licensing growth.The company ended the quarter with $131.3 million in cash and short-term investments. Cash and cash equivalents were $20.4 million and short-term investments were $110.9 million."Our full-year 2025 results reflect disciplined execution across the business, with revenue performance at the high end of our guidance range despite a challenging post-election comparison," commented Darryle Burnham, Chief Financial Officer of Newsmax. "We ended the year with a strong balance sheet and increased financial flexibility following our transition to a public company, and as we look ahead, we are confident in our financial outlook and are focused on prudent investment in content, technology and distribution initiatives that support sustainable, long-term shareholder value."<h2 class="st-heading-2">Outlook</h2>Newsmax said it expects full-year revenue of $212 million to $216 million, representing 13% year-over-year growth at the midpoint of the range.&nbsp;“As we enter 2026 , we believe Newsmax is entering this next chapter from a position of strength, supported by a solid financial foundation, expanding distribution and a clear focus on sustainable, long-term growth for our shareholders," said Christopher Ruddy, Chief Executive Officer of Newsmax.&nbsp;<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment around NMAX trended in ‘bullish’ territory amid ‘normal’ message volume.&nbsp;NMAX shares are down 23% so far this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Newsmax logo is seen displayed on a smartphone screen. 

Newsmax reported total quarterly revenues of $52.2 million for the three-month period ended December 31, 2025, representing a 9.6% year-over-year increase.

iShares Morningstar Small-Cap Growth ETF

iShares Russell 2000 ETF

Newsmax Inc

ProShares Ultra Russell2000

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

ACVF News